As biotechnology start navigating complex regulatory and stakeholder areas to bring to market an innovative product with potentially significant benefits for public health? This case focuses on the challenges facing Ventria Bioscience, a small biotechnology firm based in California. The company has developed innovative technologies for the "growing" medical proteins useful in the treatment of diarrhea in children in the genetically modified rice. The company's efforts to obtain regulatory approval in California, to commercialize his invention met with a storm of opposition from a wide range of stakeholders including environmental, food safety activists, consumer advocates, and rice farmers. The case of an obstacle encountered Ventria, as they try to commercialize his invention in the context of the wider debate on the ethics of herbal medicine. This case is suitable for upper division undergraduate or graduate course of business, small business, management of technology or biotechnology. This, of course, is in the best position to discuss the regulatory framework and stakeholder relations. In addition, it can be used in a segment on the technology or relationships with stakeholders in business and society. "Hide
by Anne T. Lawrence Source: Richard Ivey School of Business Foundation 11 pages. Publication Date: January 22, 2009. Prod. #: 909M11-PDF-ENG
Related Case Solutions & Analyses:
Disclosure Leaks and Slips: Issues and Strategies for Prohibiting Employee Communication
Siebel Systems: Anatomy of a Sale Part 1
Ethan Berman at RiskMetrics Group (A)
Research Proposal Format-Thesis 1
Growing Managers: Moving from Team Member to Team Leader
Aspada: In Search of the Right Structure for Impact Investing
Manila Water Company
getClarity Inc. (B)
Bhagwati Products Limited – Making in India for Micromax
EBS in China
